The revenue for Uproleselan sodium is expected to reach an annual total of $183 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Uproleselan sodium Overview

Uproleselan sodium (GMI-1271) is under the development for the treatment of acute myeloid leukemia (AML), coronavirus disease 2019 (COVID-19) pneumonia, myelodysplastic syndrome, chronic myelogenous leukemia and Inflammatory diseases. The drug candidate is administered through intravenous route. It acts by targeting E-selectin. GMI-1271 is a mimetic of naturally occurring carbohydrate (GlycoMimetics). It was also under development for deep venous thrombosis, pancreatic cancer, multiple myeloma and breast cancer.

GlycoMimetics Overview

GlycoMimetics is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$0.1 million for the fiscal year ended December 2022 (FY2022), a decrease of 93.5% over FY2021. The operating loss of the company was US$47.4 million in FY2022, compared to an operating loss of US$63.5 million in FY2021. The net loss of the company was US$46.7 million in FY2022, compared to a net loss of US$63.4 million in FY2021.

For a complete picture of Uproleselan sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.